Compare Stocks: LVTX, CRBP, ABOS, and CHRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.66 -0.4%	$2.39	$1.21 ▼ $3.60	$192.85M	0.36	323,187 shs	412,838 shs
CHRS Coherus Oncology	$1.15 -4.2%	$1.42	$1.03 ▼ $2.62	$185.40M	0.98	828,348 shs	1.22 million shs
CRBP Corbus Pharmaceuticals	$10.49 +4.0%	$8.99	$7.12 ▼ $20.56	$188.39M	2.59	305,780 shs	869,296 shs
LVTX LAVA Therapeutics	$1.74	$1.72	$1.17 ▼ $1.83	$45.77M	0.5	187,834 shs	N/A

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	0.00%	+9.43%	+18.67%	+22.48%	+88.03%
CHRS Coherus Oncology	0.00%	-5.51%	-14.29%	-19.46%	+14.29%
CRBP Corbus Pharmaceuticals	0.00%	-0.79%	+11.99%	+1.41%	+9.08%
LVTX LAVA Therapeutics	0.00%	0.00%	0.00%	0.00%	+14.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.66 -0.4%	$2.39	$1.21 ▼ $3.60	$192.85M	0.36	323,187 shs	412,838 shs
CHRS Coherus Oncology	$1.15 -4.2%	$1.42	$1.03 ▼ $2.62	$185.40M	0.98	828,348 shs	1.22 million shs
CRBP Corbus Pharmaceuticals	$10.49 +4.0%	$8.99	$7.12 ▼ $20.56	$188.39M	2.59	305,780 shs	869,296 shs
LVTX LAVA Therapeutics	$1.74	$1.72	$1.17 ▼ $1.83	$45.77M	0.5	187,834 shs	N/A

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	0.00%	+9.43%	+18.67%	+22.48%	+88.03%
CHRS Coherus Oncology	0.00%	-5.51%	-14.29%	-19.46%	+14.29%
CRBP Corbus Pharmaceuticals	0.00%	-0.79%	+11.99%	+1.41%	+9.08%
LVTX LAVA Therapeutics	0.00%	0.00%	0.00%	0.00%	+14.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	2.33	Hold	$8.00	200.75% Upside
CHRS Coherus Oncology	2.75	Moderate Buy	$8.67	653.62% Upside
CRBP Corbus Pharmaceuticals	2.60	Moderate Buy	$41.00	290.85% Upside
LVTX LAVA Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest LVTX, CRBP, ABOS, and CHRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	CRBP Corbus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00
8/7/2026	CHRS Coherus Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$52.00 ➝ $48.00
8/7/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $35.00
7/17/2026	CRBP Corbus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	ABOS Acumen Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	CRBP Corbus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$44.00 ➝ $34.00
6/17/2026	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$54.00 ➝ $52.00
5/27/2026	CRBP Corbus Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$38.00 ➝ $30.00
5/26/2026	CRBP Corbus Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/26/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$1.16 per share	N/A
CHRS Coherus Oncology	$42.17M	4.21	N/A	N/A	$0.50 per share	2.30
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$8.40 per share	N/A
LVTX LAVA Therapeutics	$4.99M	9.17	N/A	N/A	$1.06 per share	1.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$121.33M	-$1.63	N/A	N/A	N/A	N/A	-136.27%	-81.64%	N/A
CHRS Coherus Oncology	$168.02M	-$1.03	N/A	N/A	N/A	-259.41%	-222.75%	-52.11%	11/5/2026 (Estimated)
CRBP Corbus Pharmaceuticals	-$78.54M	-$6.19	N/A	N/A	N/A	N/A	-87.05%	-74.22%	N/A
LVTX LAVA Therapeutics	-$25.11M	-$0.86	N/A	N/A	N/A	N/A	-107.63%	-35.06%	N/A

Latest LVTX, CRBP, ABOS, and CHRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ABOS Acumen Pharmaceuticals	-$0.3593	-$0.45	-$0.0907	-$0.45	N/A	N/A
8/6/2026	Q2 2026	CRBP Corbus Pharmaceuticals	-$1.26	-$1.81	-$0.55	-$1.81	N/A	N/A
8/5/2026	Q2 2026	CHRS Coherus Oncology	-$0.25	-$0.19	+$0.06	-$0.13	$14.41 million	$14.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.21	2.47	2.47
CHRS Coherus Oncology	0.61	1.77	1.70
CRBP Corbus Pharmaceuticals	N/A	5.71	5.71
LVTX LAVA Therapeutics	N/A	12.27	12.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
CHRS Coherus Oncology	72.82%
CRBP Corbus Pharmaceuticals	64.64%
LVTX LAVA Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	10.20%
CHRS Coherus Oncology	7.22%
CRBP Corbus Pharmaceuticals	3.50%
LVTX LAVA Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	72.23 million	64.86 million	Optionable
CHRS Coherus Oncology	330	154.50 million	143.35 million	Optionable
CRBP Corbus Pharmaceuticals	40	18.67 million	18.02 million	Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable

LVTX, CRBP, ABOS, and CHRS Headlines

Recent News About These Companies

Brokerages Set LAVA Therapeutics N.V. (NASDAQ:LVTX) PT at $2.69

November 16, 2025 | defenseworld.netD

LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq

November 13, 2025 | globenewswire.com

LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline

November 10, 2025 | globenewswire.com

Insider Selling: LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Sells 690,239 Shares of Stock

October 21, 2025 | insidertrades.com

Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement

October 20, 2025 | prnewswire.com

LAVA Therapeutics N.V. Announces Amendment to Tender Offer and Extension of Extraordinary General Meeting Date

October 17, 2025 | quiverquant.comQ

LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Sells $73,436.44 in Stock

October 16, 2025 | insidertrades.com

LAVA Therapeutics N.V. Stock (LVTX) Opinions on Insider Sales and Acquisition Delays

October 11, 2025 | quiverquant.comQ

Insider Selling: LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Sells 28,954 Shares of Stock

October 11, 2025 | insidertrades.com

LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

September 30, 2025 | globenewswire.com

LAVA Therapeutics N.V. (LVTX) - Yahoo Finance

August 20, 2025 | finance.yahoo.com

LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders

August 8, 2025 | prnewswire.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX)

August 7, 2025 | prnewswire.com

Jefferies Downgrades LAVA Therapeutics N.V. (LVTX)

August 5, 2025 | msn.com

LAVA Therapeutics Shares Climb on Buyout Deal with XOMA Royalty

August 4, 2025 | msn.com

XOMA Royalty Announces Dual Acquisitions of HilleVax and LAVA Therapeutics

August 4, 2025 | msn.com

LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders

August 4, 2025 | businesswire.com

LAVA Therapeutics Shareholders Approve Key Proposals in Meeting

June 13, 2025 | tipranks.com

Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation

May 16, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, CRBP, ABOS, and CHRS Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$2.66 -0.01 (-0.37%)

As of 04:00 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Coherus Oncology NASDAQ:CHRS

$1.15 -0.05 (-4.17%)

As of 04:00 PM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Corbus Pharmaceuticals NASDAQ:CRBP

$10.49 +0.40 (+3.96%)

As of 04:00 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

LAVA Therapeutics NASDAQ:LVTX

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LVTX, CRBP, ABOS, and CHRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LVTX, CRBP, ABOS, and CHRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LVTX, CRBP, ABOS, and CHRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, CRBP, ABOS, and CHRS Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Coherus Oncology NASDAQ:CHRS

Corbus Pharmaceuticals NASDAQ:CRBP

LAVA Therapeutics NASDAQ:LVTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LVTX, CRBP, ABOS, and CHRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LVTX, CRBP, ABOS, and CHRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LVTX, CRBP, ABOS, and CHRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, CRBP, ABOS, and CHRS Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Coherus Oncology NASDAQ:CHRS

Corbus Pharmaceuticals NASDAQ:CRBP

LAVA Therapeutics NASDAQ:LVTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools